Small Bowel Microbiota Characterization in Healthy Individuals Before and After Consumption of a Western Diet

Sponsor
Mayo Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT03266536
Collaborator
Icahn School of Medicine at Mount Sinai (Other), Colorado State University (Other), University of Minnesota (Other), Imperial College London (Other)
16
1
2
4.3
3.7

Study Details

Study Description

Brief Summary

Does the small bowel microbiota in healthy individuals change after consumption of a Western diet?

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Western diet
N/A

Detailed Description

The gut microbiota is increasingly being implicated in disease. However, due to difficulty accessing the small bowel (i.e. requiring upper endoscopy) and the relative paucity of bacteria in this area (secondary to luminal flow and bactericidal bile acids/gastric acid), the small bowel microbiota is infrequently evaluated in any studies of this nature. The small bowel microbiota continues to remain an unexplored area of the gastrointestinal tract. Characterization of the microbial community and its function is the first step in determining how it potentially affects health and disease.

Study Design

Study Type:
Interventional
Actual Enrollment :
16 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Small Bowel Microbiota Characterization in Healthy Individuals Before and After Consumption of a Western Diet
Actual Study Start Date :
Jan 9, 2017
Actual Primary Completion Date :
May 16, 2017
Actual Study Completion Date :
May 19, 2017

Arms and Interventions

Arm Intervention/Treatment
No Intervention: No western diet

Participants will undergo one-time testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will be finished with testing after the upper endoscopy is complete.

Experimental: Western diet

Participants will undergo a first day of testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will then consume a Western diet for 7 days before a second day of identical testing (blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies).

Behavioral: Western diet
Western diet for 7 days: the meals in this Western diet will be provided by the Clinical Research and Trials Unit (CRTU) after participants meet with the nutrition staff (to discuss food preferences, how to obtain the meals). The meals will reflect a typical Western diet: a low fiber, high sugar diet with weight maintenance calories with < 10 grams fiber per day, and a typical US macronutrient calorie distribution of 50% carbs, 35% fat and 15% protein, with no alcohol. At least 50% of carbohydrates will be provided as simple sugars.

Outcome Measures

Primary Outcome Measures

  1. Transcriptional changes in gut microbiota present in stool. [Baseline, approximately three weeks.]

    DNA extraction from stool samples will be done using standard assays.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adults between (and including) 18-65 years old.

  • On a baseline healthy diet characterized by:

  • High fiber of ≥ 14 g/1000 calories/day

  • < 10% of daily calories from added sugar

  • At least 5 servings of fruit and vegetables per day

  • < or = 13% of daily calories from saturated fat

Exclusion Criteria:
  • Patients who do not meet the above diet requirements.

  • Known diagnosis of inflammatory bowel disease, microscopic colitis, celiac disease or other inflammatory conditions.

  • Presence of abdominal symptoms based on baseline questionnaire.

  • Commercial oral antibiotic or probiotic use within the past 4 weeks.

  • Pregnancy or plans to become pregnant within the study time frame

  • Vulnerable adults

  • Any other disease(s), condition(s) or habit(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic Rochester Minnesota United States 55905

Sponsors and Collaborators

  • Mayo Clinic
  • Icahn School of Medicine at Mount Sinai
  • Colorado State University
  • University of Minnesota
  • Imperial College London

Investigators

  • Principal Investigator: Purna C Kashyap, M.B.B.S., Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Purna C. Kashyap, MBBS, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT03266536
Other Study ID Numbers:
  • 16-006388
First Posted:
Aug 30, 2017
Last Update Posted:
May 4, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Purna C. Kashyap, MBBS, Principal Investigator, Mayo Clinic

Study Results

No Results Posted as of May 4, 2022